STG-001 ( DrugBank: STG-001 )


1 disease
IDDisease name (Link within this page)Number of trials
301Macular dystrophy1

301. Macular dystrophy


Clinical trials : 45 Drugs : 46 - (DrugBank : 12) / Drug target genes : 9 - Drug target pathways : 67
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04489511
(ClinicalTrials.gov)
October 1, 202021/7/2020Study of STG-001 in Subjects With Stargardt DiseaseA Phase 2a Study of the Safety, Pharmacokinetics and Pharmacodynamics of STG-001 in Subjects With Stargardt Disease (STGD1) Caused by Autosomal Recessive Mutation in ATP Binding Cassette Subfamily A Member 4 (ABCA4) GeneStargardt Disease-1Drug: STG-001Stargazer Pharmaceuticals, Inc.NULLCompleted18 Years55 YearsAll10Phase 2United States